ACADIA Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
125.01 M |
Public Float |
78.76 M |
ACADIA Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.1 |
Market Cap |
$3.91 B |
Shares Outstanding |
144.17 M |
Public Float |
142.3 M |
Address |
3611 Valley Centre Drive San Diego California 92130 United States |
Employees | - |
Website | http://www.acadia-pharm.com |
Updated | 07/08/2019 |
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. The company was founded by Mark R. |